Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Resistance

Efflux-Mediated Resistance to New Oxazolidinones and Pleuromutilin Derivatives in Escherichia coli with Class Specificities in the Resistance-Nodulation-Cell Division-Type Drug Transport Pathways

Sabine Schuster, Martina Vavra, Winfried V. Kern
Sabine Schuster
aDivision of Infectious Diseases, Department of Medicine II, University Hospital and Medical Center, Freiburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martina Vavra
aDivision of Infectious Diseases, Department of Medicine II, University Hospital and Medical Center, Freiburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Winfried V. Kern
aDivision of Infectious Diseases, Department of Medicine II, University Hospital and Medical Center, Freiburg, Germany
bFaculty of Medicine, Albert-Ludwigs-University, Freiburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.01041-19
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

A major contribution of the resistance-nodulation-cell division (RND)-transporter AcrB to resistance to oxazolidinones and pleuromutilin derivatives in Escherichia coli was confirmed. However, we discovered significant differences in efflux inhibitor activities, specificities of the homologous pump YhiV (MdtF), and the impact of AcrB pathway mutations. Particularly, entrance channel double-mutation I38F I671T and distal binding pocket mutation F615A revealed class-specific transport routes of oxazolidinones and pleuromutilin derivatives. The findings could contribute to the understanding of the RND-type multidrug transport pathways.

INTRODUCTION

The emergence of multidrug resistance (MDR) in Gram-negative pathogens has surpassed the supply of new antibiotics by far. Resistance-nodulation-cell division (RND)-type efflux transporters, such as AcrB from Escherichia coli, play a crucial role in MDR development (1). Their function is proton-motive force (PMF) dependent, and many of them are characterized by a remarkably broad substrate compatibility (2). AcrB constitutes the major MDR efflux pump in E. coli, with constitutive expression in wild-type strains and stable overexpression due to drug exposure (3). Close homologs of AcrB are the E. coli MDR transporters AcrF and YhiV (MdtF), which supposedly play a minor role, since at least in vitro, their expression could only be triggered after AcrB inactivation (4, 5). Among substrates extruded by AcrB are “Gram-positive drugs,” including members from the relatively new class of fully synthetic oxazolidinones, such as linezolid and tedizolid (6), and the upcoming semisynthetic pleuromutilin derivatives (7). Agents from both classes target intracellular bacterial protein biosynthesis at the translational level. Only the oxazolidinones linezolid and tedizolid and the pleuromutilin retapamulin have been in use for human treatment, but new compounds are under development even against Gram-negative pathogens (7–10).

We evaluated the impact of RND-type transporters on the susceptibility to available oxazolidinones and pleuromutilins in E. coli using standard broth microdilution assays as described previously (11). We included wild-type acrB and efflux-deficient strains (3, 5, 12), mutants expressing acrF and yhiV, and eight AcrB substrate pathway mutants (11, 13, 14) (Table 1). The oxazolidinones tested comprised the experimental agents sutezolid (10) and radezolid (9) and the oxazolidinone-fluoroquinolone conjugate cadazolid (15). For completeness, we included previous data for linezolid (5, 13) and tedizolid (data for the latter are already available for wild-type E. coli, a ΔAcrB mutant, and the I38F I671T strain [6, 11]). Among the pleuromutilins, we tested the veterinary drugs tiamulin and valnemulin as well as retapamulin and their precursor pleuromutilin.

View this table:
  • View inline
  • View popup
TABLE 1

Strains and mutants used in this study

High efflux compatibility was confirmed for both drug classes as demonstrated by ≥64-fold increased susceptibilities due to acrB deletion. Notably, overexpression versus constitutive acrB expression caused 16- and ≥128-fold increased resistance to radezolid and cadazolid, respectively (Table 2). To exclude efflux-independent effects due to smaller amounts of integral membrane proteins in a deletion mutant, we engineered an AcrB mutant D408A (Table 1). This mutation has been shown to prevent PMF generation without compromising the incorporation of functionless AcrB proteins (16, 17). We proved similar susceptibilities of the D408A and ΔAcrB mutants and the triple-knockout (TKO) mutant additionally lacking AcrF and YhiV (Table 2). The contribution of other transporters to MDR appeared negligible as shown by previous expression studies with acrB-deficient E. coli mutants (5, 6). Among the drugs tested, only the susceptibility to linezolid was significantly increased further in the ΔAcrB mutant by the PMF-inhibitor CCCP at 10 μM (Table 2), a concentration not far from the intrinsic MIC of the mutant (20 μM), but 5 μM CCCP did not show any impact (data not shown). Notably, resistance breakpoints for linezolid and tedizolid (4 μg/ml and 0.5 μg/ml, respectively, with Staphylococcus spp. [EUCAST clinical breakpoint tables v. 6.0]) were not reached in the efflux-deficient mutants. However, susceptibility increases appeared promising with radezolid, cadazolid, and the pleuromutilins regarding repurposing options for Gram-negative application under efflux inhibition.

View this table:
  • View inline
  • View popup
TABLE 2

Susceptibilities of E. coli strains expressing wild-type and mutated RND-type transporters

The efflux pump inhibitor (EPI) 1-(1-naphthylmethyl)-piperazine (NMP) (18) enhanced the activity of oxazolidinones up to 32-fold but only up to 2-fold that of the pleuromutilin derivatives. In contrast, with Phe-Arg-β-naphthylamide (PAβN), an EPI with proven outer membrane activity (19), at least 16-fold enhancement was found with all of the pleuromutilins tested (Table 2). The differing EPI activities might give an additional hint on the drug pathway specificities.

The homologous transporter AcrF can almost completely replace AcrB (1, 4, 5), also with respect to the oxazolidinones and pleuromutilins tested (Table 2). In contrast, the substrate range of YhiV is narrower. For instance, linezolid is a poor substrate (5), and this was also the case with radezolid. However, the efflux of tedizolid, sutezolid, and the pleuromutilins appeared significantly less impeded as shown by MIC decreases in the yhiV-expressing mutant that were far from those occurring due to efflux deficiency (Table 2). Surprisingly, YhiV mediated high resistance to the fluoroquinolone-oxazolidinone conjugate cadazolid, whose activity was restored when knocking out yhiV (Table 2). The reason for the distinct specificities of YhiV remains to be elucidated.

Regarding AcrB substrate pathway mutations investigated in this study, we could broadly define those revealing a single compound effect, marginal effects on resistance to drugs from both classes, class-independent overall resistance decreases, and an oxazolidinone or a pleuromutilin specificity. A unique impact occurred from mutation F617A located at the so-called G-loop (switch-loop) separating the distal from the proximal substrate binding pockets (20). It significantly increased the susceptibility only to the largest member of the pleuromutilin derivatives, valnemulin (molecular weight [MW], 564.8), whereas minor (≤4-fold) or no effects were seen with the other agents tested (Table 2). Notably, adjacent G-loop mutation G616N severely affecting macrolide resistance in E. coli (14, 20) did not cause any significant alterations with either pleuromutilins or oxazolidinones. Similar marginal effects with drugs from both classes appeared from distal binding pocket mutations F136A and F628A. In contrast, mutation F610A located across the G-loop (Fig. 1) severely increased the susceptibility to nearly all drugs from both classes. A minor impact was only found on resistances to linezolid and sutezolid, with MIC decreases of no more than 4-fold (Table 2). Sutezolid differs from linezolid only by sulfur replacing the oxygen of the morpholine ring.

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

AcrB binding state monomer (PDB 2HRT, chain B); visualization using PyMOL (Molecular Graphics System version 2.1.1, Schrödinger, LLC). (A) Part of the AcrB binding state monomer shown as cartoon (side view from the periplasmic cleft). PC1, PC2, PN1, and PN2, subdomains of the porter domain; Dd, docking domain; TM, transmembrane domain. (B) Enlarged part of the porter domain, with PC1 clipped. Blue sticks, phenylalanine side chains of the distal binding pocket; gray sphere, position of G616 (no side chain); red sticks, isoleucine side chains constituting a narrowing in the lower porter domain; red and black dashed-line ovals, residues critical for the efflux of oxazolidinones and pleuromutilin derivatives, respectively.

A significant oxazolidinone-specific impact appeared from double mutation I38F I671T located in a putative entrance channel of the lower porter domain (Fig. 1). It decreased the resistance to all of the tested oxazolidinones up to 64-fold, whereas the effects with pleuromutilin derivatives remained negligible (Table 2). It was shown previously that substitution of I38 and/or I671 by bulkier residues predominantly impedes the efflux of smaller drugs, whereas larger compounds, such as macrolides and rifamycins, supposedly use another entrance pathway (11). Notably, in contrast to that for the pleuromutilin derivatives (MW, >490), resistance to the smaller pleuromutilin (MW, 378.5) was significantly affected by I38F I671T (Table 2). Among the distal binding pocket mutations, the most remarkable oxazolidinone-specific impact occurred with F178A (Table 2, Fig. 1), whereas the largest pleuromutilin specificity arose from mutation F615A removing a phenyl residue from the G-loop (Fig. 1). In this mutant, the susceptibility to all pleuromutilins was significantly increased but not that to the oxazolidinones (except cadazolid) (Table 2).

Our study reveals evidence of different pathways for oxazolidinones and pleuromutilin derivatives through RND-type transporters. The knowledge of class-specific efflux determinants could elucidate structural requirements of competitive inhibitors or efflux-incompatible drugs.

ACKNOWLEDGMENTS

This work was supported in part by the Innovative Medicines Initiative (IMI) Joint Undertaking project no. 115525 ND4BB Translocation (http://www.translocation.eu, contributions from the European Union Seventh Framework Program and EFPIA companies).

We have no conflicts of interest to declare.

FOOTNOTES

    • Received 21 May 2019.
    • Returned for modification 7 June 2019.
    • Accepted 13 June 2019.
    • Accepted manuscript posted online 17 June 2019.
  • Supplemental material for this article may be found at https://doi.org/10.1128/AAC.01041-19.

  • Copyright © 2019 American Society for Microbiology.

All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Li XZ,
    2. Plesiat P,
    3. Nikaido H
    . 2015. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clin Microbiol Rev 28:337–418. doi:10.1128/CMR.00117-14.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Pos KM
    . 2009. Drug transport mechanism of the AcrB efflux pump. Biochim Biophys Acta 1794:782–793. doi:10.1016/j.bbapap.2008.12.015.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Kern WV,
    2. Oethinger M,
    3. Jellen-Ritter AS,
    4. Levy SB
    . 2000. Non-target gene mutations in the development of fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother 44:814–820. doi:10.1128/aac.44.4.814-820.2000.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Jellen-Ritter AS,
    2. Kern WV
    . 2001. Enhanced expression of the multidrug efflux pumps AcrAB and AcrEF associated with insertion element transposition in Escherichia coli mutants selected with a fluoroquinolone. Antimicrob Agents Chemother 45:1467–1472. doi:10.1128/AAC.45.5.1467-1472.2001.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Bohnert JA,
    2. Schuster S,
    3. Fähnrich E,
    4. Trittler R,
    5. Kern WV
    . 2007. Altered spectrum of multidrug resistance associated with a single point mutation in the Escherichia coli RND-type MDR efflux pump YhiV (MdtF). J Antimicrob Chemother 59:1216–1222. doi:10.1093/jac/dkl426.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Schuster S,
    2. Vavra M,
    3. Schweigger TM,
    4. Rossen JWA,
    5. Matsumura Y,
    6. Kern WV
    . 2017. Contribution of AcrAB-TolC to multidrug resistance in an Escherichia coli sequence type 131 isolate. Int J Antimicrob Agents 50:477–481. doi:10.1016/j.ijantimicag.2017.03.023.
    OpenUrlCrossRef
  7. 7.↵
    1. Paukner S,
    2. Riedl R
    . 2017. Pleuromutilins: potent drugs for resistant bugs-mode of action and resistance. Cold Spring Harb Perspect Med 7:a027110. doi:10.1101/cshperspect.a027110.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Novak R,
    2. Shlaes DM
    . 2010. The pleuromutilin antibiotics: a new class for human use. Curr Opin Investig Drugs 11:182–191.
    OpenUrlPubMedWeb of Science
  9. 9.↵
    1. Sutcliffe JA
    . 2011. Antibiotics in development targeting protein synthesis. Ann N Y Acad Sci 1241:122–152. doi:10.1111/j.1749-6632.2011.06323.x.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Yip PC,
    2. Kam KM,
    3. Lam ET,
    4. Chan RC,
    5. Yew WW
    . 2013. In vitro activities of PNU-100480 and linezolid against drug-susceptible and drug-resistant Mycobacterium tuberculosis isolates. Int J Antimicrob Agents 42:96–97. doi:10.1016/j.ijantimicag.2013.03.002.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Schuster S,
    2. Vavra M,
    3. Kern WV
    . 2016. Evidence of a substrate-discriminating entrance channel in the lower porter domain of the multidrug resistance efflux pump AcrB. Antimicrob Agents Chemother 60:4315–4323. doi:10.1128/AAC.00314-16.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. George AM,
    2. Levy SB
    . 1983. Amplifiable resistance to tetracycline, chloramphenicol, and other antibiotics in Escherichia coli: involvement of a non-plasmid-determined efflux of tetracycline. J Bacteriol 155:531–540.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Bohnert JA,
    2. Schuster S,
    3. Seeger MA,
    4. Fähnrich E,
    5. Pos KM,
    6. Kern WV
    . 2008. Site-directed mutagenesis reveals putative substrate binding residues in the Escherichia coli RND efflux pump AcrB. J Bacteriol 190:8225–8229. doi:10.1128/JB.00912-08.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Wehmeier C,
    2. Schuster S,
    3. Fähnrich E,
    4. Kern WV,
    5. Bohnert JA
    . 2009. Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance. Antimicrob Agents Chemother 53:329–330. doi:10.1128/AAC.00921-08.
    OpenUrlFREE Full Text
  15. 15.↵
    1. Locher HH,
    2. Seiler P,
    3. Chen X,
    4. Schroeder S,
    5. Pfaff P,
    6. Enderlin M,
    7. Klenk A,
    8. Fournier E,
    9. Hubschwerlen C,
    10. Ritz D,
    11. Kelly CP,
    12. Keck W
    . 2014. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrob Agents Chemother 58:892–900. doi:10.1128/AAC.01830-13.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Takatsuka Y,
    2. Nikaido H
    . 2006. Threonine-978 in the transmembrane segment of the multidrug efflux pump AcrB of Escherichia coli is crucial for drug transport as a probable component of the proton relay network. J Bacteriol 188:7284–7289. doi:10.1128/JB.00683-06.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Wang-Kan X,
    2. Blair JMA,
    3. Chirullo B,
    4. Betts J,
    5. La Ragione RM,
    6. Ivens A,
    7. Ricci V,
    8. Opperman TJ,
    9. Piddock L
    . 2017. Lack of AcrB efflux function confers loss of virulence on Salmonella enterica serovar Typhimurium. mBio 8:e00968-17. doi:10.1128/mBio.00968-17.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Bohnert JA,
    2. Kern WV
    . 2005. Selected arylpiperazines are capable of reversing multidrug resistance in Escherichia coli overexpressing RND efflux pumps. Antimicrob Agents Chemother 49:849–852. doi:10.1128/AAC.49.2.849-852.2005.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Schuster S,
    2. Bohnert JA,
    3. Vavra M,
    4. Rossen JW,
    5. Kern WV
    . 2019. Proof of an outer membrane target of the efflux inhibitor Phe-Arg-β-naphthylamide from random mutagenesis. Molecules 24:470. doi:10.3390/molecules24030470.
    OpenUrlCrossRef
  20. 20.↵
    1. Eicher T,
    2. Cha HJ,
    3. Seeger MA,
    4. Brandstätter L,
    5. El-Delik J,
    6. Bohnert JA,
    7. Kern WV,
    8. Verrey F,
    9. Grütter MG,
    10. Diederichs K,
    11. Pos KM
    . 2012. Transport of drugs by the multidrug transporter AcrB involves an access and a deep binding pocket that are separated by a switch-loop. Proc Natl Acad Sci U S A 109:5687–5692. doi:10.1073/pnas.1114944109.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Efflux-Mediated Resistance to New Oxazolidinones and Pleuromutilin Derivatives in Escherichia coli with Class Specificities in the Resistance-Nodulation-Cell Division-Type Drug Transport Pathways
Sabine Schuster, Martina Vavra, Winfried V. Kern
Antimicrobial Agents and Chemotherapy Aug 2019, 63 (9) e01041-19; DOI: 10.1128/AAC.01041-19

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Efflux-Mediated Resistance to New Oxazolidinones and Pleuromutilin Derivatives in Escherichia coli with Class Specificities in the Resistance-Nodulation-Cell Division-Type Drug Transport Pathways
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Efflux-Mediated Resistance to New Oxazolidinones and Pleuromutilin Derivatives in Escherichia coli with Class Specificities in the Resistance-Nodulation-Cell Division-Type Drug Transport Pathways
Sabine Schuster, Martina Vavra, Winfried V. Kern
Antimicrobial Agents and Chemotherapy Aug 2019, 63 (9) e01041-19; DOI: 10.1128/AAC.01041-19
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

AcrB
RND-type transporter
YhiV (MdtF)
efflux
oxazolidinones
pleuromutilins

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596